RxDoctor Payments Data

Ronald Witteles, MD

Advanced Heart Failure and Transplant Cardiology · Stanford, CANPI 1285779389

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (59.2%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Pfizer at 40.7% of the total. Among advanced heart failure and transplant cardiology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$250,589in general payments, 2019–2025

Across 125 payments — averaging $2004.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$102K
  • Alnylam Pharmaceuticals Inc.$53K
  • Novo Nordisk AS$46K
  • AstraZeneca$26K
  • Bridgebio Pharma, Inc.$10K
  • Akcea Therapeutics, Inc.$5K
  • plus $9K from 5 others
$3,876,236in research payments, 2019–2025

Across 128 payments — averaging $30,283 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alnylam Pharmaceuticals Inc.$2.6M
  • Pfizer$488K
  • Janssen Research & Development, LLC$417K
  • Ionis Pharmaceuticals, Inc.$390K
  • AstraZeneca$18K
  • Genentech, Inc.$7K

What the payments were for

  • Consulting fees$148,27559%
  • Speaking & faculty fees$32,34213%
  • Travel & lodging$67,02827%
  • Food & beverage$2,9441%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer(2 entities)46$102,052
Alnylam Pharmaceuticals Inc.42$52,577
Novo Nordisk AS11$45,514
AstraZeneca(2 entities)14$25,859
Bridgebio Pharma, Inc.3$10,175
Akcea Therapeutics, Inc.3$5,393
Regeneron2$5,265
Janssen Scientific Affairs, LLC1$1,768
Astrazeneca AB1$1,611
Pfizer Corporation Hong Kong Limited1$224
Medtronic1$153

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$250,589 in reported general payments places this provider in the 90th percentile of 111 advanced heart failure and transplant cardiology providers in California.

See all advanced heart failure and transplant cardiology providers in California

Medicare billing

Part B allowed, 2024
$121,225
Medicare patients
402
Services billed
1,003

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis621$14,562,044
VyndaqelTafamidis Meglumine95$2,145,241
JardianceEmpagliflozin339$464,787
EliquisApixaban250$341,777
EntrestoSacubitril/Valsartan169$262,583
FarxigaDapagliflozin Propanediol56$61,333
XareltoRivaroxaban34$35,726
Eplerenone74$9,744
Spironolactone313$3,405
Metoprolol Succinate183$3,148
Carvedilol249$2,873
MethotrexateMethotrexate Sodium42$2,786
Ezetimibe40$2,345
Bumetanide36$2,035
Furosemide249$1,813

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel, Eliquis$102,052$17,049,062966 claims
AstraZenecaFarxiga$25,859$61,33356 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 111 advanced heart failure and transplant cardiology providers in California.

Other advanced heart failure and transplant cardiology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →